Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.
J Clin Pharmacol
; 60 Suppl 1: S160-S178, 2020 10.
Article
en En
| MEDLINE
| ID: mdl-33205429
ABSTRACT
Since 2016, results from physiologically based pharmacokinetic (PBPK) analyses have been routinely found in the clinical pharmacology section of regulatory applications submitted to the US Food and Drug Administration (FDA). In 2018, the Food and Drug Administration's Office of Clinical Pharmacology published a commentary summarizing the application of PBPK modeling in the submissions it received between 2008 and 2017 and its impact on prescribing information. In this commentary, we provide an update on the application of PBPK modeling in submissions received between 2018 and 2019 and highlight a few notable examples.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Farmacología Clínica
/
United States Food and Drug Administration
/
Simulación por Computador
/
Farmacocinética
/
Aprobación de Drogas
/
Modelos Biológicos
Tipo de estudio:
Prognostic_studies
País/Región como asunto:
America do norte
Idioma:
En
Revista:
J Clin Pharmacol
Año:
2020
Tipo del documento:
Article